Floor J. Backes, MD

Floor J. Backes, MD, an associate professor in the Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer CenterJames, discusses the immunotherapeutic options available for treatment of patients with ovarian cancer.

There are PD-1/PD-L1 antibodies, as well as antiCTLA-4 antibodies, says Backes. There are also many combinations with these different agents currently in development in clinical trials for ovarian cancer.

Backes notes that the checkpoint inhibitors have not shown very high responses in patients with ovarian cancer. The responses with checkpoint inhibitors have only ranged from 10% to 15%. Because of this, combination regimens are under evaluation to see if we can make these more effective. Investigators are combining immunotherapy with antiangiogenic agents, antiCTLA-4 antibodies, or PARP inhibitors.

With these combinations, it always seems like we can achieve higher responses than we can with the single agents alone, Backes concludes.

<< View more resources and information regarding gynecologic cancers

Videos

Floor J. Backes, MD, discusses the immunotherapeutic options available for treatment of patients with ovarian cancer.

Combination Regimens May Improve Responses in Ovarian Cancer

Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discusses the side effects associated with

the combination lenvatinib (Lenvima) plus paclitaxel in patients with recurrent endometrial and platinum-resistant epithelial ovarian cancer.

The toxicities were typical to that of other chemotherapy agents, says Backes. This includes cytopenia, anemia, leukopenia, and some thrombocytopenia. It was mostly the white and red cells that were affected.

Floor J. Backes, MD, discusses the side effects associated with the combination lenvatinib plus paclitaxel in patients with recurrent endometrial and platinum-resistant epithelial ovarian cancer.

Investigating Toxicities With Lenvatinib Plus Paclitaxel in Ovarian and Endometrial Cancers

Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discusses

investigating the combination of lenvatinib (Lenvima) and paclitaxel in patients with recurrent ovarian, fallopian tube, or peritoneal cancers.

The primary goal of the study was to find a recommended phase II dose. The trial established an 80 mg weekly of paclitaxel and a daily dose of lenvatinib at 60 mg, says Backes. The combination appeared safe and tolerable in these patients.

Floor J. Backes, MD,&nbsp;discusses the results from a phase I trial investigating the combination of lenvatinib (Lenvima) and paclitaxel in patients with recurrent ovarian, fallopian tube, or peritoneal cancers.

Floor J. Backes, MD | Authors

Articles

Combination Regimens May Improve Responses in Ovarian Cancer

Investigating Toxicities With Lenvatinib Plus Paclitaxel in Ovarian and Endometrial Cancers

Evaluating the Benefits of Lenvatinib and Paclitaxel in Recurrent Gynecologic Cancers